Enanta Pharma (ENTA) Misses Q2 EPS by 5c
Get Alerts ENTA Hot Sheet
Join SI Premium – FREE
Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of ($0.06), $0.05 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $14 million versus the consensus estimate of $13.05 million.
For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: RH, Estee Lauder rise; Tesla falls
- Oxford Industries (OXM) Reports In-Line Q4 EPS, provides guidance
- Can-Fite BioPharma (CANF) Reports FY23 Results, Issues Clinical Update
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!